🏷

Classifications

Harrison's Part

🔗

Mappings

MONDO

MONDO:0008523 Blau syndrome

MONDO:0008523 is the primary disease concept for familial and sporadic Blau syndrome.

◆

Subtypes

2

Familial Blau Syndrome

Familial disease results from an inherited heterozygous pathogenic NOD2 variant. It is not a separate clinical phenotype, and penetrance can vary for some alleles.

Show evidence (2 references)

PMID:41678017 SUPPORT Other

"Blau syndrome is an autosomal dominant disease primarily occurring in children and is caused by highly penetrant NOD2 variants"

The review supports the usual autosomal dominant familial presentation.

PMID:36192768 SUPPORT Human Clinical

"We reported a novel C483W NOD2 mutation underlining BS with incomplete penetrance."

A family with an asymptomatic variant-bearing parent shows that high penetrance is not universal.

Early-Onset Sarcoidosis (Sporadic)

Sporadic disease commonly reflects a de novo heterozygous NOD2 variant and is clinically indistinguishable from familial Blau syndrome. Early-onset sarcoidosis is the historical name for this presentation.

Show evidence (2 references)

PMID:17968944 SUPPORT Human Clinical

"Of the 12 cases, 58.3% were sporadic, due to de novo mutations"

Spanish cohort confirms majority of cases are sporadic with de novo NOD2 mutations.

PMID:17009307 SUPPORT Human Clinical

"Blau syndrome and its sporadic counterpart, early-onset sarcoidosis, share an identical phenotype featuring the classic triad of arthritis, dermatitis, and uveitis and are associated with mutations of CARD15 in 50-90% of cases"

International registry confirms identical phenotype between familial and sporadic forms.

?

Discussions and Knowledge Gaps

3

How can IFN-gamma-primed ligand-independent NF-kappaB activation be reconciled with loss of canonical NOD2-RIPK2-IRF4 cross-regulation in Blau syndrome?

CONTROVERSY OPEN controversy_blau_nod2_signaling_model

Attached to

pathophysiology#IFN-γ-Primed Mutant NOD2 Inflammatory Signaling pathophysiology#Defective NOD2-RIPK2-IRF4 Cross-Regulation

Both models use disease-relevant variants but differ in cell system, stimulation context, and measured pathway output. The entry therefore models them as potentially complementary branches rather than collapsing genetic gain of function into universal constitutive NF-kappaB activation.

Show evidence (2 references)

PMID:28587749 SUPPORT In Vitro

"IFN-γ treatment induced ligand-independent nuclear factor κB activation and proinflammatory cytokine production."

Isogenic and patient-derived macrophages support a priming-dependent activation model.

PMID:36189261 SUPPORT In Vitro

"NOD2 plasmids expressing various Blau mutations in HEK293 cells result in reduced NOD2 activation of RIPK2 and correspondingly reduced NOD2 activation of NF-κB."

HEK293 cell experiments support reduced canonical NOD2-RIPK2 and NF-kappaB signaling.

Which steroid-sparing or biologic regimen best prevents irreversible ocular and articular damage in Blau syndrome?

KNOWLEDGE GAP OPEN gap_blau_comparative_treatment_efficacy

Attached to

treatments#Methotrexate Steroid-Sparing Therapy treatments#Anti-TNF Biologic Therapy treatments#Salvage IL-1 Receptor Antagonist Therapy treatments#Emerging Tofacitinib Therapy

Published treatment evidence is dominated by case reports and small observational cohorts. Even the uveitis meta-analysis could not identify a preferred systemic treatment, and long-term TNF-inhibitor responses can be lost.

Show evidence (2 references)

PMID:40147219 SUPPORT Human Clinical

"The data show that there is not enough evidence to establish a preferred treatment for managing uveitis in BS."

The systematic review explicitly identifies comparative uncertainty.

PMID:41673771 SUPPORT Human Clinical

"relapse or secondary loss of efficacy occurred in 6 (46.2%) patients, necessitating treatment adjustments."

Long-term observational data demonstrate that initial biologic response may not persist.

How should a rare NOD2 variant be interpreted when the phenotype or family segregation is incomplete?

INTERPRETATION OPEN interpretation_blau_nod2_variant_penetrance

Attached to

genetic#NOD2

Although the gene-disease relationship is definitive and many hotspot variants are highly penetrant, incomplete penetrance and variants of uncertain significance occur. Classification must integrate phenotype, segregation, population data, and functional evidence.

Show evidence (2 references)

PMID:36192768 SUPPORT Human Clinical

"A novel C483W NOD2 mutation was identify in the proband and her asymptomatic father."

The family directly demonstrates incomplete penetrance.

PMID:38927735 SUPPORT Human Clinical

"Variants of unknown significance pose a significant challenge regarding their contribution to etiopathogenesis of autoinflammatory diseases."

The case series cautions against equating an uncertain variant with a molecular diagnosis.

⚙

Pathophysiology

9

Pathogenic NOD2 NACHT-Domain Variants

Heterozygous pathogenic NOD2 variants, often clustered in the central nucleotide-binding/NACHT domain, are the primary molecular lesion. Their clinical classification as gain-of-function alleles does not by itself resolve the context-dependent signaling behavior observed in different experimental systems.

NOD2 hgnc:5331

Downstream

IFN-γ-Primed Mutant NOD2 Inflammatory Signaling IFN-gamma increases NOD2 abundance and permits ligand-independent inflammatory signaling in disease-specific macrophage models.

Defective NOD2-RIPK2-IRF4 Cross-Regulation A second mechanistic model links Blau variants to reduced canonical NOD2-RIPK2 signaling and loss of IRF4-mediated restraint on parallel innate responses.

Show evidence (2 references)

PMID:11528384 SUPPORT Human Clinical

"We have identified three missense mutations in the nucleotide-binding domain (NBD) of CARD15/NOD2 in four French and German families with Blau syndrome"

Landmark paper identifying CARD15/NOD2 NBD mutations as the cause of Blau syndrome.

CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z SUPPORT Other

ClinGen independently classifies the autosomal dominant NOD2 disease relationship as definitive.

IFN-γ-Primed Mutant NOD2 Inflammatory Signaling

In isogenic iPSC-derived and patient-derived macrophages, IFN-gamma upregulates mutant NOD2 and enables ligand-independent NF-kappaB activation and proinflammatory cytokine production.

macrophage CL:0000235

NOD2 hgnc:5331

NOD2 signaling pathway GO:0070431 ↑ INCREASED canonical NF-kappaB signal transduction GO:0007249 ↑ INCREASED

Downstream

Dysregulated Innate Cytokine Response IFN-gamma-primed mutant NOD2 drives abnormal inflammatory cytokine production.

Show evidence (2 references)

PMID:28587749 SUPPORT In Vitro

"Patient-derived macrophages demonstrated a similar IFN-γ-dependent inflammatory response."

Patient-derived cells reproduce the response observed in the isogenic iPSC system.

PMID:35711422 SUPPORT In Vitro

"abnormal cytokine expression in macrophages from untreated patients requires IFNγ stimulation, and that anti-TNF treatment corrects the abnormalities associated with Blau syndrome, even in the presence of IFNγ"

Patient-derived macrophage work independently emphasizes IFN-gamma priming and TNF-responsive cytokine abnormalities.

Defective NOD2-RIPK2-IRF4 Cross-Regulation

Blau-associated NOD2 variants can reduce MDP-responsive RIPK2 signaling and IRF4 induction, weakening NOD2-mediated suppression of concurrent TLR responses. This model differs from simple constitutive activation.

NOD2 hgnc:5331

NOD2 signaling pathway GO:0070431 ↓ DECREASED

Downstream

Dysregulated Innate Cytokine Response Loss of IRF4-mediated restraint permits exaggerated cytokine responses to concurrent innate signals.

Show evidence (1 reference)

PMID:36189261 SUPPORT Model Organism

"BS-NOD2 also exhibit defects in cross-regulation of innate responses underlying inflammation."

In vivo experiments identify failed innate-response cross-regulation.

Dysregulated Innate Cytokine Response

Context-dependent mutant-NOD2 signaling and defective innate cross-regulation converge on abnormal macrophage cytokine production. The precise cytokine hierarchy in human lesions remains incompletely defined.

macrophage CL:0000235

inflammatory response GO:0006954 ↑ INCREASED

Downstream

Granulomatous Inflammation Sustained dysregulated innate inflammation is modeled upstream of tissue granuloma formation.

Show evidence (1 reference)

PMID:28587749 SUPPORT In Vitro

"IFN-γ treatment induced ligand-independent nuclear factor κB activation and proinflammatory cytokine production."

The isogenic macrophage model demonstrates abnormal cytokine production.

Granulomatous Inflammation

Noncaseating epithelioid granulomas are the pathologic hallmark and occur in skin, synovium, and other involved tissues. How the competing mutant-NOD2 signaling models generate and maintain granulomas remains incompletely resolved.

Epithelioid macrophage CL:0002150 Multinucleated giant cell CL:0000647

Inflammatory Response GO:0006954 ↑ INCREASED

Downstream

Granulomatous Synovitis and Tenosynovitis Granulomatous synovitis causes progressive polyarthritis.

Ocular Inflammation Granulomatous uveitis threatens vision.

Cutaneous Granulomatosis Non-caseating granulomas form in the dermis.

Visceral and Vascular Involvement Granulomatous inflammation extends to visceral organs and the vasculature.

Fever Systemic granulomatous autoinflammation can include recurrent fever.

Show evidence (1 reference)

PMID:17968944 SUPPORT Human Clinical

"Blau syndrome and early-onset sarcoidosis are NOD2 gene-associated chronic autoinflammatory diseases characterized by skin rash, arthritis, and/or eye involvement, with noncaseating granulomata as their pathologic hallmark"

Confirms non-caseating granulomas as the defining pathological feature.

Granulomatous Synovitis and Tenosynovitis

Chronic granulomatous synovial and tendon-sheath inflammation produces boggy polyarthritis, contractures, and impaired function. The characteristic arthropathy can be severe but is often radiographically nonerosive.

Synovial cell CL:0000214

Downstream

Granulomatous Arthritis Granulomatous synovitis manifests clinically as polyarticular arthritis.

Camptodactyly Chronic granulomatous tenosynovitis and joint involvement can present with camptodactyly.

Bone Dysplastic Changes Dysplastic bone changes are associated with the characteristic arthropathy, although the causal route from NOD2 signaling to bone morphology is unknown.

Show evidence (1 reference)

PMID:25416713 SUPPORT Human Clinical

"The most frequently involved joints at presentation were wrists, ankles, knees and PIPs"

Confirms characteristic joint distribution pattern in Blau syndrome.

Ocular Inflammation

Granulomatous uveitis, typically panuveitis, is the most sight-threatening manifestation. Can progress to cataracts, glaucoma, band keratopathy, and blindness if untreated.

Inflammatory Response GO:0006954 ↑ INCREASED

Downstream

Granulomatous Uveitis Ocular granulomatous inflammation manifests as uveitis/panuveitis.

Visual Impairment Chronic uveitis and its complications produce visual impairment.

Cataract Cataract is a complication of chronic ocular inflammation.

Glaucoma Chronic uveitis and its treatment can be complicated by glaucoma.

Show evidence (2 references)

PMID:25416713 SUPPORT Human Clinical

"Ocular disease was documented in 25 of 31 patients, with vitreous inflammation in 64% and moderate-severe visual loss in 33%"

Confirms high prevalence of ocular disease with significant visual morbidity.

PMID:17009307 SUPPORT Human Clinical

"Eye disease was bilateral in 21 of 22 patients and was complicated by glaucoma in 6 of 22 patients and by cataracts in 50% of patients"

Documents severe visual complications including cataracts and glaucoma.

Cutaneous Granulomatosis

Skin involvement manifests as a symmetrical, tan-colored, papular or lichenoid rash, often the earliest clinical sign. Biopsy reveals non-caseating granulomas in the dermis.

Downstream

Granulomatous Dermatitis Dermal granulomas manifest as the characteristic rash or dermatitis.

Show evidence (1 reference)

PMID:17009307 SUPPORT Human Clinical

"Cutaneous presentation was the most common"

International registry confirms skin rash as the most common presenting feature.

Visceral and Vascular Involvement

Beyond the classic triad, Blau syndrome can involve visceral organs (liver, kidney, lung) and vasculature. Interstitial lung disease and vasculitis represent expanded manifestations that may be life-threatening.

Downstream

Vasculitis Expanded vascular involvement manifests as vasculitis.

Interstitial Lung Disease Expanded visceral involvement can include interstitial lung disease.

Show evidence (2 references)

PMID:25416713 SUPPORT Human Clinical

"Expanded manifestations (visceral, vascular) beyond the classic clinical triad were seen in 52%"

Multicentre study reveals visceral and vascular involvement in over half of patients.

PMID:40350497 SUPPORT Human Clinical

"Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively"

Chinese cohort quantifies frequency of vasculitis and lung involvement.

✶

Histopathology

1

Noncaseating Epithelioid Granulomas

Skin or synovial tissue can show noncaseating granulomas composed of epithelioid histiocytes and multinucleated giant cells. This finding supports Blau syndrome in the appropriate early-onset multisystem context but is not disease-specific.

Show evidence (2 references)

PMID:17968944 SUPPORT Human Clinical

"noncaseating granulomata as their pathologic hallmark"

The cohort identifies noncaseating granulomas as the defining histopathologic feature.

PMID:36192768 SUPPORT Human Clinical

"Her skin biopsy revealed noncaseating granulomas inflammation with multinucleated giant cells."

A genetically confirmed case documents noncaseating granulomas with multinucleated giant cells.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

11

Cardiovascular 1

Vasculitis OCCASIONAL HP:0002633

Show evidence (1 reference)

PMID:40350497 SUPPORT Human Clinical

"Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively"

Chinese cohort shows vasculitis in 27.7% of patients.

Eye 4

Granulomatous Uveitis VERY_FREQUENT Panuveitis HP:0012121

Show evidence (2 references)

PMID:25416713 SUPPORT Human Clinical

"Ocular disease was documented in 25 of 31 patients, with vitreous inflammation in 64% and moderate-severe visual loss in 33%"

Ocular disease present in 81% of the multicentre cohort.

PMID:17009307 SUPPORT Human Clinical

"Isolated eye disease was never the presenting symptom, but significant/severe visual impairment was observed in 41% of patients"

International registry confirms significant visual morbidity from uveitis.

Visual Impairment FREQUENT HP:0000505

Show evidence (1 reference)

PMID:17009307 SUPPORT Human Clinical

"significant/severe visual impairment was observed in 41% of patients"

International registry documents visual impairment in 41% of patients.

Cataract FREQUENT HP:0000518

Show evidence (1 reference)

PMID:17009307 SUPPORT Human Clinical

"cataracts in 50% of patients"

International registry documents cataracts in half of patients with ocular disease.

Glaucoma OCCASIONAL HP:0000501

Show evidence (1 reference)

PMID:17009307 SUPPORT Human Clinical

"Eye disease was bilateral in 21 of 22 patients and was complicated by glaucoma in 6 of 22 patients and by cataracts in 50% of patients"

Glaucoma affected 6 of 22 patients with eye disease in the international registry.

Immune 1

Granulomatous Dermatitis FREQUENT Skin rash HP:0000988

Show evidence (2 references)

PMID:17009307 SUPPORT Human Clinical

"Cutaneous presentation was the most common"

International registry confirms skin rash as the most common presenting feature.

PMID:40350497 SUPPORT Human Clinical

"At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%"

Rash/dermatitis present in 72.3% of Chinese cohort.

Metabolism 1

Fever FREQUENT Recurrent fever HP:0001954

Show evidence (2 references)

PMID:40350497 SUPPORT Human Clinical

"At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%"

Fever present in 34% of Chinese cohort at baseline.

PMID:17968944 SUPPORT Human Clinical

"Novel atypical manifestations such as persistent fever and myocardiopathy were also observed"

Spanish cohort identifies persistent fever as an atypical manifestation.

Musculoskeletal 2

Camptodactyly HP:0012385

Show evidence (1 reference)

PMID:38927735 SUPPORT Human Clinical

"In two individuals from one family, only camptodactyly was noted, while another member had camptodactyly in combination with non-active uveitis and angioid streaks"

Brichova 2024 case series documents camptodactyly as a presenting feature in multiple family members with Blau syndrome.

Bone Dysplastic Changes FREQUENT Skeletal dysplasia HP:0002652

Show evidence (1 reference)

PMID:25416713 SUPPORT Human Clinical

"Previously unknown dysplastic bony changes were found in two-thirds of patients"

Multicentre study discovers bone dysplastic changes in 66% of patients, a novel finding with potential diagnostic value.

Respiratory 1

Interstitial Lung Disease OCCASIONAL Abnormal pulmonary interstitial morphology HP:0006530

Show evidence (1 reference)

PMID:40350497 SUPPORT Human Clinical

"Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively"

Chinese cohort shows interstitial lung disease in 17% of patients.

Other 1

Granulomatous Arthritis VERY_FREQUENT Polyarticular arthritis HP:0005764

Show evidence (3 references)

PMID:25416713 SUPPORT Human Clinical

"Arthritis, documented in all but one patient, was oligoarticular in 7, polyarticular in 23"

Multicentre study shows arthritis in 30/31 patients, polyarticular in the majority.

PMID:40350497 SUPPORT Human Clinical

"At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%"

Chinese cohort confirms arthritis in 93.6% of patients.

PMID:17009307 SUPPORT Human Clinical

"Arthritis was polyarticular in 96% of patients"

International registry confirms polyarticular pattern in the vast majority.

🧬

Genetic Associations

1

NOD2 (Heterozygous pathogenic variants)

Gene: NOD2 hgnc:5331 relationship_type: CAUSATIVE

Autosomal dominant

Show evidence (6 references)

PMID:11528384 SUPPORT Human Clinical

"We have identified three missense mutations in the nucleotide-binding domain (NBD) of CARD15/NOD2 in four French and German families with Blau syndrome"

Landmark paper identifying CARD15/NOD2 as the causative gene with mutations in the NBD.

PMID:25416713 SUPPORT Human Clinical

"Of the 31 patients, 11 carried the p.R334W NOD2 mutation, 9 the p.R334Q and 11 various other NOD2 missense mutations; 20 patients were sporadic and 11 from five BS pedigrees"

Multicentre study shows R334W and R334Q are the most common mutations.

PMID:17968944 SUPPORT Human Clinical

"NOD2 analysis revealed 1 heterozygous mutation in each patient, and familial studies confirmed its full penetrance"

Confirms heterozygous mutations with full penetrance.

+ 3 more references

Variants (2)

p.Arg334Trp (R334W)

Recurrent pathogenic missense variant c.1000C>T in the NOD/NACHT domain. It was the most frequent single variant in the international prospective cohort.

Show evidence (1 reference)

PMID:25416713 SUPPORT Human Clinical

"Of the 31 patients, 11 carried the p.R334W NOD2 mutation, 9 the p.R334Q and 11 various other NOD2 missense mutations"

Multicentre cohort confirms p.R334W is the single most common Blau syndrome mutation.

p.Arg334Gln (R334Q)

Recurrent pathogenic missense variant c.1001G>A affecting the same NACHT-domain residue as p.Arg334Trp.

Show evidence (1 reference)

PMID:25416713 SUPPORT Human Clinical

"Of the 31 patients, 11 carried the p.R334W NOD2 mutation, 9 the p.R334Q and 11 various other NOD2 missense mutations"

Multicentre cohort documents p.R334Q in 9 of 31 Blau patients alongside R334W.

🗃️

External Assertions

1

ClinGen NOD2–Blau syndrome gene-disease validity assertion

ClinGen gene disease validity CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z

ClinGen classifies the autosomal dominant NOD2–Blau syndrome relationship as definitive.

Show evidence (1 reference)

CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z SUPPORT Other

The structured ClinGen assertion supplies the gene, disease, inheritance, and definitive classification.

💊

Medical Actions

6

Regular Ophthalmic Monitoring

Category: Monitoring Action: eye examination Ontology label: Eye Examination NCIT:C38060

Repeated slit-lamp and posterior-segment examinations are essential because ocular inflammation can become chronic panuveitis and systemic inflammatory markers may not reflect intraocular activity.

Show evidence (1 reference)

PMID:38180755 SUPPORT Human Clinical

"Uveitis associated with Blau syndrome commonly leads to severe, chronic panuveitis, requiring long-term systemic immunosuppression."

Longitudinal ocular outcomes justify sustained specialist monitoring.

Systemic Corticosteroids as Bridging Therapy

Category: Therapeutic Action: corticosteroid agent therapy Ontology label: Systemic Corticosteroid Therapy NCIT:C122080

Agent: prednisolone CHEBI:8378

Systemic glucocorticoids can suppress acute inflammatory activity while a steroid-sparing regimen is established. Long-term monotherapy is generally inadequate and exposes children to cumulative toxicity.

Show evidence (2 references)

PMID:37735224 SUPPORT Other

"High doses of corticosteroids are considered as a bridging therapy in Blau syndrome."

The proposed management algorithm limits high-dose corticosteroids to a bridging role.

PMID:40350497 SUPPORT Human Clinical

"Approximately 95.7% patients (45 patients) were treated with combination of prednisolone and methotrexate"

The cohort documents frequent combined use but does not isolate corticosteroid efficacy.

Methotrexate Steroid-Sparing Therapy

Category: Therapeutic Action: immunosuppressive therapy Ontology label: Immunosuppressive Therapy NCIT:C15261

Agent: methotrexate CHEBI:44185

Methotrexate is commonly used for articular or ocular disease as a steroid-sparing conventional DMARD. Evidence is observational, and pooled uveitis data do not establish it as a preferred agent.

Target Phenotypes: Polyarticular arthritis HP:0005764 Panuveitis HP:0012121

Show evidence (2 references)

PMID:37735224 SUPPORT Other

"Methotrexate should be initiated if the patient has articular or ocular involvement."

The review's proposed algorithm places methotrexate after bridging corticosteroids.

PMID:40147219 SUPPORT Human Clinical

"The data show that there is not enough evidence to establish a preferred treatment for managing uveitis in BS."

The meta-analysis limits confidence in methotrexate or any other preferred systemic uveitis regimen.

Anti-TNF Biologic Therapy

Category: Therapeutic Action: anti-TNF biologic therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: adalimumab NCIT:C65216 infliximab NCIT:C1789

Monoclonal TNF inhibitors such as adalimumab or infliximab are used for persistent uveitis or arthritis. Cohorts show frequent initial responses, but relapse and secondary loss of efficacy are common, and comparative evidence remains insufficient.

Mechanism Target:

INHIBITS Dysregulated Innate Cytokine Response

Show evidence (1 reference)

PMID:35711422 SUPPORT In Vitro

"anti-TNF treatment corrects the abnormalities associated with Blau syndrome, even in the presence of IFNγ"

Patient-derived macrophages provide mechanistic support for TNF blockade.

Target Phenotypes: Polyarticular arthritis HP:0005764 Panuveitis HP:0012121

Show evidence (2 references)

PMID:41673771 SUPPORT Human Clinical

"While 6 (46.2%) patients achieved sustained stability, relapse or secondary loss of efficacy occurred in 6 (46.2%) patients, necessitating treatment adjustments."

Long-term follow-up documents both durable control and frequent secondary failure.

PMID:40147219 SUPPORT Human Clinical

"The proportion of children showing improvement of uveitis was 20 % (95 % CI 2-46) and 22 % (95 % CI3-47) for cDMARDs and bDMARDs respectively (χ20.23, p = 0.631)."

The pooled literature does not demonstrate superior uveitis improvement with biologic DMARDs.

Salvage IL-1 Receptor Antagonist Therapy

Category: Therapeutic Action: IL-1 receptor antagonist therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: anakinra CHEBI:231683

Anakinra has produced improvement in an individual refractory case, but evidence is too limited to establish general efficacy or a preferred place in therapy.

Mechanism Target:

INHIBITS Dysregulated Innate Cytokine Response

Show evidence (1 reference)

PMID:17968944 SUPPORT Human Clinical

"the pathogenesis of pediatric granulomatous arthritis may involve interleukin-1-mediated events"

The cohort provides limited clinical and cytokine evidence for an IL-1-responsive branch.

Show evidence (1 reference)

PMID:17968944 SUPPORT Human Clinical

"In the patient who received anakinra treatment, all clinical inflammatory symptoms improved and plasma cytokine levels normalized"

This is single-patient evidence and is retained only as a salvage-treatment signal.

Emerging Tofacitinib Therapy

Category: Therapeutic Action: JAK inhibitor therapy Ontology label: Pharmacotherapy NCIT:C15986

Agent: tofacitinib CHEBI:71200

Tofacitinib suppresses IFN-gamma-induced NOD2 expression in cell models and has retrospective clinical evidence in refractory Blau syndrome. It remains an emerging option under prospective evaluation rather than an established standard.

Mechanism Target:

INHIBITS IFN-γ-Primed Mutant NOD2 Inflammatory Signaling

Show evidence (1 reference)

PMID:37415984 SUPPORT In Vitro

"Tofacitinib suppressed the induction of NOD2 by IFNγ, thereby inhibiting the production of pro-inflammatory cytokines"

The cell model directly supports inhibition of the IFN-gamma/NOD2 branch.

Target Phenotypes: Polyarticular arthritis HP:0005764 Panuveitis HP:0012121

Show evidence (2 references)

PMID:37415984 SUPPORT In Vitro

"Tofacitinib suppressed the induction of NOD2 by IFNγ, thereby inhibiting the production of pro-inflammatory cytokines"

iPSC-derived myeloid cell studies demonstrate tofacitinib suppresses NOD2 expression and cytokine production.

PMID:40233998 SUPPORT Human Clinical

"TOF could be an effective therapeutic option for patients with BS who demonstrate resistance to TNFi or corticosteroids."

The multicenter retrospective cohort supplies clinical support while retaining nonrandomized uncertainty.

🔬

Diagnosis

4

Early-onset granulomatous triad and multisystem assessment

Suspect Blau syndrome in a child with papular granulomatous dermatitis, boggy arthritis or tenosynovitis, and uveitis, even when the full triad has not yet appeared. Assess for vascular, pulmonary, renal, hepatic, neurologic, and other systemic manifestations.

diagnostic procedure NCIT:C18020

Show evidence (2 references)

PMID:40456554 SUPPORT Other

"Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain-of-function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated."

The review defines the clinical pattern that should prompt diagnostic evaluation.

PMID:19479837 SUPPORT Human Clinical

"NOD2-associated PGA can be a multisystem disorder with significant visceral involvement."

The combined cohorts support evaluation beyond the classic triad.

NOD2 molecular genetic testing

Sequence NOD2, with an autoinflammatory gene panel or broader testing when appropriate, to identify a heterozygous pathogenic or likely pathogenic variant. Variant interpretation must integrate phenotype, segregation, penetrance, and functional data rather than treating every NOD2 variant as diagnostic.

molecular genetic testing NCIT:C19770

Show evidence (2 references)

PMID:37941393 SUPPORT Human Clinical

"Targeted NOD2 sequencing established the molecular diagnosis of Blau syndrome in nearly one-fifth of these cases and provided clinically relevant information for patient-care decisions."

Targeted sequencing reclassified a substantial selected subgroup previously diagnosed with JIA.

PMID:38927735 SUPPORT Human Clinical

"The probands from families 1 and 2 carried pathogenic variants in NOD2 (NM_022162.3): c.1001G>A p.(Arg334Gln) and c.1000C>T p.(Arg334Trp), respectively."

The case series illustrates molecular confirmation and the need to distinguish pathogenic variants from variants of uncertain significance.

Skin biopsy for granulomatous inflammation

Biopsy of an active skin lesion can demonstrate noncaseating granulomas and multinucleated giant cells. Histology is supportive rather than sufficient because other inflammatory, infectious, and immunodeficiency disorders can also be granulomatous.

skin biopsy NCIT:C51692

Show evidence (1 reference)

PMID:36192768 SUPPORT Human Clinical

"Her skin biopsy revealed noncaseating granulomas inflammation with multinucleated giant cells."

The genetically confirmed case demonstrates the supportive biopsy pattern.

Comprehensive ophthalmic examination

Slit-lamp and posterior-segment assessment are needed at diagnosis because ocular disease can be bilateral and may progress despite apparently controlled systemic inflammation.

eye examination NCIT:C38060

Show evidence (1 reference)

PMID:25416713 SUPPORT Human Clinical

"Ocular disease was documented in 25 of 31 patients, with vitreous inflammation in 64% and moderate-severe visual loss in 33%"

The high ocular burden supports comprehensive eye evaluation at diagnosis.

📈

Progression

3

Early cutaneous and articular disease

Dermatitis and joint disease commonly emerge in infancy or early childhood, often before ocular disease.

Show evidence (1 reference)

PMID:40456554 SUPPORT Other

"Skin and joint findings typically emerge by age 2 years, with ocular involvement appearing around age 4 years."

The review describes the usual temporal sequence of the classic triad.

Chronic ocular disease

Uveitis can evolve into chronic panuveitis with progressive visual loss and cataract, glaucoma, or retinal complications despite systemic treatment.

Show evidence (1 reference)

PMID:38180755 SUPPORT Human Clinical

"Among patients with documented uveitis lasting 10 years or more, all of them developed panuveitis."

Longitudinal follow-up documents progression of persistent ocular disease to panuveitis.

Long-term multisystem morbidity

Delayed recognition and incompletely controlled inflammation can lead to joint deformity, visual morbidity, and variable systemic organ involvement.

Show evidence (1 reference)

PMID:41673771 SUPPORT Human Clinical

"The substantial diagnostic delay (median: 19 years, range: 7–29 years, IQR: 18.5–21 years) likely contributed to the high prevalence of clinical manifestations, including arthritis (13,100%), ocular involvement (12, 92.3%), joint deformity (10, 76.9%), and the full classical triad (9, 69.2%)."

The longitudinal cohort links prolonged diagnostic delay with substantial ocular and articular morbidity.

🌍

Epidemiology

1

Rare pediatric autoinflammatory granulomatosis

Blau syndrome is rare and usually begins in childhood. No robust population-based prevalence estimate is established in the cited cohorts.

Show evidence (1 reference)

PMID:40456554 SUPPORT Other

"Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain-of-function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated."

The review characterizes the disorder as rare and pediatric without supplying a population rate.

🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Blau Syndrome:

Juvenile Idiopathic Arthritis MONDO:0011429

Overlapping Features Juvenile idiopathic arthritis can combine childhood arthritis and uveitis, but papular granulomatous dermatitis, boggy tenosynovitis, noncaseating granulomas, or a familial pattern should prompt reassessment for Blau syndrome.

Distinguishing Features

Heterozygous pathogenic NOD2 variant supports Blau syndrome
Noncaseating granulomatous dermatitis or synovitis supports Blau syndrome
The complete dermatitis-arthritis-uveitis triad is more characteristic of Blau syndrome

Show evidence (1 reference)

PMID:37941393 SUPPORT Human Clinical

"Targeted sequencing was conducted on NOD2 gene to detect diagnostic variants classified as pathogenic or likely pathogenic for Blau syndrome."

The diagnostic-yield study directly addresses selected patients initially classified as JIA.

📊

Related Datasets

1

Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages geo:GSE98454

Bulk RNA sequencing of Blau syndrome p.R334W iPSC-derived macrophages, CRISPR-corrected isogenic cells, and wild-type control cells under untreated, IFN-gamma, MDP, and combined stimulation conditions.

human BULK RNA SEQ

macrophage CL:0000235

Conditions: Blau syndrome p.Arg334Trp CRISPR-corrected isogenic control wild-type control

PMID:28587749

GEO GSE98454 contains 12 samples spanning mutant, gene-corrected, and wild-type iPSC-derived macrophages with IFN-gamma and/or MDP perturbation.

Show evidence (1 reference)

PMID:28587749 SUPPORT In Vitro

"RNA sequencing analysis revealed distinct transcriptional profiles of mutant macrophages both before and after IFN-γ treatment."

The publication describes the RNA-seq comparison represented by GSE98454.

🔬

Clinical Trials

2

NCT06660329 PHASE_IV ENROLLING_BY_INVITATION

Prospective cohort study evaluating the efficacy and safety of tofacitinib in 30 children with refractory Blau syndrome. The registry lists estimated completion in October 2028.

Target Phenotypes: Polyarticular arthritis HP:0005764 Panuveitis HP:0012121

Show evidence (1 reference)

clinicaltrials:NCT06660329 SUPPORT Human Clinical

"This is a prospective cohort study to observe the efficacy and safety of Tofacitinib in children with Blau syndrome (BS)"

The registry defines the prospective refractory-Blau cohort and intervention.

NCT06688838 NOT_APPLICABLE ENROLLING_BY_INVITATION

Retrospective multicenter observational study comparing glucocorticoid plus conventional DMARD, TNF-inhibitor, and tofacitinib-treated Blau syndrome cohorts; the associated results have been published.

Target Phenotypes: Polyarticular arthritis HP:0005764 Panuveitis HP:0012121

Show evidence (2 references)

clinicaltrials:NCT06688838 SUPPORT Human Clinical

"To investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort."

The registry summary specifies the observational treatment-comparison objective.

PMID:40233998 SUPPORT Human Clinical

"A 5-year, multicenter, retrospective, observational study (ClinicalTrials.gov: NCT06688838) was conducted across 7 centers, focusing on genetic profiles and the clinical manifestations of the cohort."

The publication links the reported retrospective study directly to the registry.

🐁

Animal Models

1

Mus musculus

Mice carrying a Blau-associated NOD2 mutation show defective NOD2-mediated cross-regulation and enhanced antibody-induced arthritis, modeling one proposed route from altered innate regulation to joint inflammation.

Species

Mus musculus

Show evidence (1 reference)

PMID:36189261 SUPPORT Model Organism

"Similarly, mice bearing a Blau mutation exhibit enhanced anti-collagen antibody-induced arthritis."

The mutation-bearing mouse demonstrates increased susceptibility to experimentally induced joint inflammation.

{ }

Source YAML

click to show

name: Blau Syndrome
creation_date: "2026-04-23T05:00:56Z"
category: Mendelian
parents:
- Autoinflammatory Disease
- Granulomatous Disease
classifications:
  harrisons_chapter:
  - classification_value: IMMUNE_RHEUMATOLOGIC
    evidence:
    - reference: PMID:40456554
      reference_title: "Blau Syndrome (Juvenile Systemic Granulomatosis): State-Of-The-Art Review."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain-of-function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated."
      explanation: The review classifies Blau syndrome as a systemic pediatric autoinflammatory disorder.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0008523
      label: Blau syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: MONDO:0008523 is the primary disease concept for familial and sporadic Blau syndrome.
external_assertions:
- name: ClinGen NOD2–Blau syndrome gene-disease validity assertion
  source: ClinGen
  assertion_type: gene_disease_validity
  external_id: CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z
  url: https://search.clinicalgenome.org/kb/gene-validity/CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z
  description: ClinGen classifies the autosomal dominant NOD2–Blau syndrome relationship as definitive.
  evidence:
  - reference: CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z
    reference_title: "NOD2 / Blau syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NOD2 | HGNC:5331 | Blau syndrome | MONDO:0008523 | AD | Definitive"
    explanation: The structured ClinGen assertion supplies the gene, disease, inheritance, and definitive classification.
description: >-
  Blau syndrome is a rare, usually childhood-onset, autosomal dominant
  autoinflammatory granulomatosis caused by heterozygous pathogenic variants in
  NOD2. Familial Blau syndrome and the sporadic disorder historically called
  early-onset sarcoidosis are the same disease spectrum. Granulomatous
  dermatitis, arthritis or tenosynovitis, and uveitis form the classic triad,
  but vascular, pulmonary, renal, hepatic, neurologic, and other systemic
  involvement can occur. Disease-associated NOD2 variants alter innate immune
  signaling, although the relative contributions of ligand-independent
  signaling and defective cross-regulation remain unresolved.
disease_term:
  preferred_term: Blau syndrome
  term:
    id: MONDO:0008523
    label: Blau syndrome
synonyms:
- BLAUS
- Early-onset sarcoidosis
- EOS
- Familial juvenile systemic granulomatosis
- Arthrocutaneouveal granulomatosis
- Jabs syndrome
- Pediatric granulomatous arthritis
has_subtypes:
- name: Familial Blau syndrome
  display_name: Familial Blau Syndrome
  description: >-
    Familial disease results from an inherited heterozygous pathogenic NOD2
    variant. It is not a separate clinical phenotype, and penetrance can vary
    for some alleles.
  evidence:
  - reference: PMID:41678017
    reference_title: "NOD2-Related Multisystem Inflammatory Disorders and Recent Advances."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Blau syndrome is an autosomal dominant disease primarily occurring in children and is caused by highly penetrant NOD2 variants"
    explanation: The review supports the usual autosomal dominant familial presentation.
  - reference: PMID:36192768
    reference_title: "Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We reported a novel C483W NOD2 mutation underlining BS with incomplete penetrance."
    explanation: A family with an asymptomatic variant-bearing parent shows that high penetrance is not universal.
- name: Sporadic Blau syndrome
  display_name: Early-Onset Sarcoidosis (Sporadic)
  description: >-
    Sporadic disease commonly reflects a de novo heterozygous NOD2 variant and
    is clinically indistinguishable from familial Blau syndrome. Early-onset
    sarcoidosis is the historical name for this presentation.
  evidence:
  - reference: PMID:17968944
    reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 12 cases, 58.3% were sporadic, due to de novo mutations"
    explanation: Spanish cohort confirms majority of cases are sporadic with de novo NOD2 mutations.
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blau syndrome and its sporadic counterpart, early-onset sarcoidosis, share an identical phenotype featuring the classic triad of arthritis, dermatitis, and uveitis and are associated with mutations of CARD15 in 50-90% of cases"
    explanation: International registry confirms identical phenotype between familial and sporadic forms.
epidemiology:
- name: Rare pediatric autoinflammatory granulomatosis
  description: >-
    Blau syndrome is rare and usually begins in childhood. No robust
    population-based prevalence estimate is established in the cited cohorts.
  evidence:
  - reference: PMID:40456554
    reference_title: "Blau Syndrome (Juvenile Systemic Granulomatosis): State-Of-The-Art Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain-of-function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated."
    explanation: The review characterizes the disorder as rare and pediatric without supplying a population rate.
progression:
- phase: Early cutaneous and articular disease
  notes: >-
    Dermatitis and joint disease commonly emerge in infancy or early childhood,
    often before ocular disease.
  evidence:
  - reference: PMID:40456554
    reference_title: "Blau Syndrome (Juvenile Systemic Granulomatosis): State-Of-The-Art Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Skin and joint findings typically emerge by age 2 years, with ocular involvement appearing around age 4 years."
    explanation: The review describes the usual temporal sequence of the classic triad.
- phase: Chronic ocular disease
  notes: >-
    Uveitis can evolve into chronic panuveitis with progressive visual loss and
    cataract, glaucoma, or retinal complications despite systemic treatment.
  evidence:
  - reference: PMID:38180755
    reference_title: "Long-Term Visual Outcome of Patients with Blau Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among patients with documented uveitis lasting 10 years or more, all of them developed panuveitis."
    explanation: Longitudinal follow-up documents progression of persistent ocular disease to panuveitis.
- phase: Long-term multisystem morbidity
  notes: >-
    Delayed recognition and incompletely controlled inflammation can lead to
    joint deformity, visual morbidity, and variable systemic organ involvement.
  evidence:
  - reference: PMID:41673771
    reference_title: "Clinical features, treatment strategies, and long-term outcomes of Blau syndrome: a 10-year experience from a Chinese cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The substantial diagnostic delay (median: 19 years, range: 7–29 years, IQR: 18.5–21 years) likely contributed to the high prevalence of clinical manifestations, including arthritis (13,100%), ocular involvement (12, 92.3%), joint deformity (10, 76.9%), and the full classical triad (9, 69.2%)."
    explanation: The longitudinal cohort links prolonged diagnostic delay with substantial ocular and articular morbidity.
pathophysiology:
- name: Pathogenic NOD2 NACHT-Domain Variants
  description: >-
    Heterozygous pathogenic NOD2 variants, often clustered in the central
    nucleotide-binding/NACHT domain, are the primary molecular lesion. Their
    clinical classification as gain-of-function alleles does not by itself
    resolve the context-dependent signaling behavior observed in different
    experimental systems.
  gene:
    preferred_term: NOD2
    term:
      id: hgnc:5331
      label: NOD2
  evidence:
  - reference: PMID:11528384
    reference_title: "CARD15 mutations in Blau syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have identified three missense mutations in the nucleotide-binding domain (NBD) of CARD15/NOD2 in four French and German families with Blau syndrome"
    explanation: Landmark paper identifying CARD15/NOD2 NBD mutations as the cause of Blau syndrome.
  - reference: CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z
    reference_title: "NOD2 / Blau syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NOD2 | HGNC:5331 | Blau syndrome | MONDO:0008523 | AD | Definitive"
    explanation: ClinGen independently classifies the autosomal dominant NOD2 disease relationship as definitive.
  downstream:
  - target: IFN-γ-Primed Mutant NOD2 Inflammatory Signaling
    description: >-
      IFN-gamma increases NOD2 abundance and permits ligand-independent
      inflammatory signaling in disease-specific macrophage models.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - IFN-gamma-dependent NOD2 upregulation in mutant macrophages
    evidence:
    - reference: PMID:28587749
      reference_title: "Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "IFN-γ acted as a priming signal through upregulation of NOD2. In iPSC-derived macrophages with mutant NOD2, IFN-γ treatment induced ligand-independent nuclear factor κB activation and proinflammatory cytokine production."
      explanation: Isogenic and patient-derived macrophage models establish the IFN-gamma-dependent branch.
  - target: Defective NOD2-RIPK2-IRF4 Cross-Regulation
    description: >-
      A second mechanistic model links Blau variants to reduced canonical
      NOD2-RIPK2 signaling and loss of IRF4-mediated restraint on parallel
      innate responses.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:36189261
      reference_title: "Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The main finding was that Blau NOD2 mutations precipitate a loss of canonical NOD2 signaling via RIPK2 and that this loss has two consequences: first, it results in defective NOD2 ligand (MDP)-mediated NF-κB activation and second, it disrupts NOD2-mediated cross-regulation whereby NOD2 downregulates concomitant innate (TLR) responses."
      explanation: Cell experiments support loss of canonical signaling and cross-regulation.
- name: IFN-γ-Primed Mutant NOD2 Inflammatory Signaling
  description: >-
    In isogenic iPSC-derived and patient-derived macrophages, IFN-gamma
    upregulates mutant NOD2 and enables ligand-independent NF-kappaB activation
    and proinflammatory cytokine production.
  gene:
    preferred_term: NOD2
    term:
      id: hgnc:5331
      label: NOD2
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: NOD2 signaling pathway
    term:
      id: GO:0070431
      label: nucleotide-binding oligomerization domain containing 2 signaling pathway
    modifier: INCREASED
  - preferred_term: canonical NF-kappaB signal transduction
    term:
      id: GO:0007249
      label: canonical NF-kappaB signal transduction
    modifier: INCREASED
  evidence:
  - reference: PMID:28587749
    reference_title: "Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Patient-derived macrophages demonstrated a similar IFN-γ-dependent inflammatory response."
    explanation: Patient-derived cells reproduce the response observed in the isogenic iPSC system.
  - reference: PMID:35711422
    reference_title: "Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "abnormal cytokine expression in macrophages from untreated patients requires IFNγ stimulation, and that anti-TNF treatment corrects the abnormalities associated with Blau syndrome, even in the presence of IFNγ"
    explanation: Patient-derived macrophage work independently emphasizes IFN-gamma priming and TNF-responsive cytokine abnormalities.
  downstream:
  - target: Dysregulated Innate Cytokine Response
    description: IFN-gamma-primed mutant NOD2 drives abnormal inflammatory cytokine production.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:28587749
      reference_title: "Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In iPSC-derived macrophages with mutant NOD2, IFN-γ treatment induced ligand-independent nuclear factor κB activation and proinflammatory cytokine production."
      explanation: The perturbation directly connects IFN-gamma priming to inflammatory output.
- name: Defective NOD2-RIPK2-IRF4 Cross-Regulation
  description: >-
    Blau-associated NOD2 variants can reduce MDP-responsive RIPK2 signaling and
    IRF4 induction, weakening NOD2-mediated suppression of concurrent TLR
    responses. This model differs from simple constitutive activation.
  gene:
    preferred_term: NOD2
    term:
      id: hgnc:5331
      label: NOD2
  biological_processes:
  - preferred_term: NOD2 signaling pathway
    term:
      id: GO:0070431
      label: nucleotide-binding oligomerization domain containing 2 signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:36189261
    reference_title: "Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "BS-NOD2 also exhibit defects in cross-regulation of innate responses underlying inflammation."
    explanation: In vivo experiments identify failed innate-response cross-regulation.
  downstream:
  - target: Dysregulated Innate Cytokine Response
    description: Loss of IRF4-mediated restraint permits exaggerated cytokine responses to concurrent innate signals.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Reduced IRF4 induction and failed suppression of TLR signaling
    evidence:
    - reference: PMID:36189261
      reference_title: "Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "TLR-stimulated cells bearing a Blau mutation exhibited enhanced in vitro cytokine responses that are quieted by lentivirus transduction of IRF4."
      explanation: IRF4 rescue directly supports the cross-regulatory link to cytokine output.
- name: Dysregulated Innate Cytokine Response
  description: >-
    Context-dependent mutant-NOD2 signaling and defective innate
    cross-regulation converge on abnormal macrophage cytokine production. The
    precise cytokine hierarchy in human lesions remains incompletely defined.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:28587749
    reference_title: "Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "IFN-γ treatment induced ligand-independent nuclear factor κB activation and proinflammatory cytokine production."
    explanation: The isogenic macrophage model demonstrates abnormal cytokine production.
  downstream:
  - target: Granulomatous Inflammation
    description: Sustained dysregulated innate inflammation is modeled upstream of tissue granuloma formation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:17968944
      reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blau syndrome and early-onset sarcoidosis are NOD2 gene-associated chronic autoinflammatory diseases characterized by skin rash, arthritis, and/or eye involvement, with noncaseating granulomata as their pathologic hallmark"
      explanation: Human disease evidence connects NOD2-associated autoinflammation to granulomas but does not resolve the intervening cytokine sequence.
- name: Granulomatous Inflammation
  description: >-
    Noncaseating epithelioid granulomas are the pathologic hallmark and occur in
    skin, synovium, and other involved tissues. How the competing mutant-NOD2
    signaling models generate and maintain granulomas remains incompletely
    resolved.
  cell_types:
  - preferred_term: Epithelioid macrophage
    term:
      id: CL:0002150
      label: epithelioid macrophage
  - preferred_term: Multinucleated giant cell
    term:
      id: CL:0000647
      label: multinucleated giant cell
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:17968944
    reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blau syndrome and early-onset sarcoidosis are NOD2 gene-associated chronic autoinflammatory diseases characterized by skin rash, arthritis, and/or eye involvement, with noncaseating granulomata as their pathologic hallmark"
    explanation: Confirms non-caseating granulomas as the defining pathological feature.
  downstream:
  - target: Granulomatous Synovitis and Tenosynovitis
    description: Granulomatous synovitis causes progressive polyarthritis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17968944
      reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blau syndrome and early-onset sarcoidosis are NOD2 gene-associated chronic autoinflammatory diseases characterized by skin rash, arthritis, and/or eye involvement, with noncaseating granulomata as their pathologic hallmark"
      explanation: The cohort connects granulomatous pathology with the articular disease.
  - target: Ocular Inflammation
    description: Granulomatous uveitis threatens vision.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17968944
      reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blau syndrome and early-onset sarcoidosis are NOD2 gene-associated chronic autoinflammatory diseases characterized by skin rash, arthritis, and/or eye involvement, with noncaseating granulomata as their pathologic hallmark"
      explanation: The cohort places eye involvement in the granulomatous disease spectrum.
  - target: Cutaneous Granulomatosis
    description: Non-caseating granulomas form in the dermis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17968944
      reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Blau syndrome and early-onset sarcoidosis are NOD2 gene-associated chronic autoinflammatory diseases characterized by skin rash, arthritis, and/or eye involvement, with noncaseating granulomata as their pathologic hallmark"
      explanation: The cohort connects the skin phenotype with noncaseating granulomatous pathology.
  - target: Visceral and Vascular Involvement
    description: Granulomatous inflammation extends to visceral organs and the vasculature.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19479837
      reference_title: "NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "NOD2-associated PGA can be a multisystem disorder with significant visceral involvement."
      explanation: The combined registry and cohort establish multisystem visceral disease in NOD2-associated Blau syndrome.
  - target: Fever
    description: Systemic granulomatous autoinflammation can include recurrent fever.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:40350497
      reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%."
      explanation: Fever is a systemic manifestation in the pediatric Blau syndrome cohort.
- name: Granulomatous Synovitis and Tenosynovitis
  description: >-
    Chronic granulomatous synovial and tendon-sheath inflammation produces
    boggy polyarthritis, contractures, and impaired function. The characteristic
    arthropathy can be severe but is often radiographically nonerosive.
  cell_types:
  - preferred_term: Synovial cell
    term:
      id: CL:0000214
      label: synovial cell
  evidence:
  - reference: PMID:25416713
    reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most frequently involved joints at presentation were wrists, ankles, knees and PIPs"
    explanation: Confirms characteristic joint distribution pattern in Blau syndrome.
  downstream:
  - target: Granulomatous Arthritis
    description: Granulomatous synovitis manifests clinically as polyarticular arthritis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25416713
      reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Arthritis, documented in all"
      explanation: Multicentre data directly support arthritis as the joint manifestation.
  - target: Camptodactyly
    description: Chronic granulomatous tenosynovitis and joint involvement can present with camptodactyly.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Chronic tenosynovitis and joint contracture limit finger extension.
    evidence:
    - reference: PMID:38927735
      reference_title: "Blau Syndrome: Challenging Molecular Genetic Diagnostics of Autoinflammatory Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "only camptodactyly was noted, while another member had camptodactyly in"
      explanation: Case evidence documents camptodactyly in NOD2-associated Blau syndrome.
  - target: Bone Dysplastic Changes
    description: >-
      Dysplastic bone changes are associated with the characteristic arthropathy,
      although the causal route from NOD2 signaling to bone morphology is unknown.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:25416713
      reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Previously unknown dysplastic bony changes were found in two-thirds of patients."
      explanation: The prospective cohort links dysplastic bone findings to Blau syndrome but does not establish their mechanism.
- name: Ocular Inflammation
  description: >
    Granulomatous uveitis, typically panuveitis, is the most sight-threatening
    manifestation. Can progress to cataracts, glaucoma, band keratopathy, and
    blindness if untreated.
  evidence:
  - reference: PMID:25416713
    reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ocular disease was documented in 25 of 31 patients, with vitreous inflammation in 64% and moderate-severe visual loss in 33%"
    explanation: Confirms high prevalence of ocular disease with significant visual morbidity.
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eye disease was bilateral in 21 of 22 patients and was complicated by glaucoma in 6 of 22 patients and by cataracts in 50% of patients"
    explanation: Documents severe visual complications including cataracts and glaucoma.
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  downstream:
  - target: Granulomatous Uveitis
    description: Ocular granulomatous inflammation manifests as uveitis/panuveitis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25416713
      reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Ocular disease was documented"
      explanation: Multicentre data support inflammatory ocular disease in Blau syndrome.
  - target: Visual Impairment
    description: Chronic uveitis and its complications produce visual impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:17009307
      reference_title: "Pediatric granulomatous arthritis: an international registry."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "significant/severe visual impairment was observed in 41% of"
      explanation: The international registry documents visual impairment in Blau syndrome.
  - target: Cataract
    description: Cataract is a complication of chronic ocular inflammation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:17009307
      reference_title: "Pediatric granulomatous arthritis: an international registry."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "glaucoma in 6 of 22 patients and by cataracts in 50% of patients."
      explanation: The international registry documents cataracts as ocular complications.
  - target: Glaucoma
    description: Chronic uveitis and its treatment can be complicated by glaucoma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:17009307
      reference_title: "Pediatric granulomatous arthritis: an international registry."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Eye disease was bilateral in 21 of 22 patients and was complicated by glaucoma in 6 of 22 patients and by cataracts in 50% of patients"
      explanation: The international registry directly documents glaucoma as an ocular complication.
- name: Cutaneous Granulomatosis
  description: >
    Skin involvement manifests as a symmetrical, tan-colored, papular or
    lichenoid rash, often the earliest clinical sign. Biopsy reveals
    non-caseating granulomas in the dermis.
  evidence:
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cutaneous presentation was the most common"
    explanation: International registry confirms skin rash as the most common presenting feature.
  downstream:
  - target: Granulomatous Dermatitis
    description: Dermal granulomas manifest as the characteristic rash or dermatitis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40350497
      reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%."
      explanation: The pediatric cohort quantifies rash/dermatitis as a common cutaneous manifestation.
- name: Visceral and Vascular Involvement
  description: >
    Beyond the classic triad, Blau syndrome can involve visceral organs
    (liver, kidney, lung) and vasculature. Interstitial lung disease and
    vasculitis represent expanded manifestations that may be life-threatening.
  evidence:
  - reference: PMID:25416713
    reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Expanded manifestations (visceral, vascular) beyond the classic clinical triad were seen in 52%"
    explanation: Multicentre study reveals visceral and vascular involvement in over half of patients.
  - reference: PMID:40350497
    reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively"
    explanation: Chinese cohort quantifies frequency of vasculitis and lung involvement.
  downstream:
  - target: Vasculitis
    description: Expanded vascular involvement manifests as vasculitis.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40350497
      reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively"
      explanation: The Chinese pediatric cohort quantifies vasculitis.
  - target: Interstitial Lung Disease
    description: Expanded visceral involvement can include interstitial lung disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:40350497
      reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively"
      explanation: The Chinese pediatric cohort quantifies interstitial lung disease.
phenotypes:
- name: Granulomatous Arthritis
  category: Musculoskeletal
  description: >
    Polyarticular boggy synovitis with non-caseating granulomas, typically
    affecting wrists, ankles, knees, and interphalangeal joints. Usually the
    presenting feature, with onset before age 4.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Polyarticular arthritis
    term:
      id: HP:0005764
      label: Polyarticular arthritis
  evidence:
  - reference: PMID:25416713
    reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Arthritis, documented in all but one patient, was oligoarticular in 7, polyarticular in 23"
    explanation: Multicentre study shows arthritis in 30/31 patients, polyarticular in the majority.
  - reference: PMID:40350497
    reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%"
    explanation: Chinese cohort confirms arthritis in 93.6% of patients.
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Arthritis was polyarticular in 96% of patients"
    explanation: International registry confirms polyarticular pattern in the vast majority.
- name: Granulomatous Uveitis
  category: Ophthalmologic
  description: >
    Bilateral panuveitis with mutton-fat keratic precipitates, posterior
    synechiae, and risk of cataracts, glaucoma, and vision loss. Most
    sight-threatening complication.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Panuveitis
    term:
      id: HP:0012121
      label: Panuveitis
  evidence:
  - reference: PMID:25416713
    reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ocular disease was documented in 25 of 31 patients, with vitreous inflammation in 64% and moderate-severe visual loss in 33%"
    explanation: Ocular disease present in 81% of the multicentre cohort.
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Isolated eye disease was never the presenting symptom, but significant/severe visual impairment was observed in 41% of patients"
    explanation: International registry confirms significant visual morbidity from uveitis.
- name: Granulomatous Dermatitis
  category: Dermatologic
  description: >
    Symmetric, tan-colored or erythematous papular rash, often ichthyosiform
    or lichenoid in character. Usually the earliest clinical manifestation,
    appearing in infancy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Skin rash
    term:
      id: HP:0000988
      label: Skin rash
  evidence:
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cutaneous presentation was the most common"
    explanation: International registry confirms skin rash as the most common presenting feature.
  - reference: PMID:40350497
    reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%"
    explanation: Rash/dermatitis present in 72.3% of Chinese cohort.
- name: Camptodactyly
  category: Musculoskeletal
  description: >
    Flexion contractures of fingers due to chronic granulomatous tenosynovitis,
    a characteristic feature of Blau syndrome joint involvement.
  phenotype_term:
    preferred_term: Camptodactyly
    term:
      id: HP:0012385
      label: Camptodactyly
  evidence:
  - reference: PMID:38927735
    reference_title: "Blau Syndrome: Challenging Molecular Genetic Diagnostics of Autoinflammatory Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In two individuals from one family, only camptodactyly was noted, while another member had camptodactyly in combination with non-active uveitis and angioid streaks"
    explanation: Brichova 2024 case series documents camptodactyly as a presenting feature in multiple family members with Blau syndrome.
- name: Fever
  category: Constitutional
  description: >
    Intermittent fevers may occur, particularly during disease flares, reflecting
    the systemic autoinflammatory nature of the condition.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Recurrent fever
    term:
      id: HP:0001954
      label: Recurrent fever
  evidence:
  - reference: PMID:40350497
    reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At baseline, incidence of fever, arthritis, rash, dermatitis and uveitis were 34%, 93.6%, 72.3% and 31.9%"
    explanation: Fever present in 34% of Chinese cohort at baseline.
  - reference: PMID:17968944
    reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Novel atypical manifestations such as persistent fever and myocardiopathy were also observed"
    explanation: Spanish cohort identifies persistent fever as an atypical manifestation.
- name: Visual Impairment
  category: Ophthalmologic
  description: >
    Progressive visual loss due to complications of chronic uveitis including
    cataracts, glaucoma, band keratopathy, and macular edema.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "significant/severe visual impairment was observed in 41% of patients"
    explanation: International registry documents visual impairment in 41% of patients.
- name: Cataract
  category: Ophthalmologic
  description: >
    Secondary cataracts develop as a complication of chronic granulomatous
    uveitis and/or prolonged corticosteroid therapy.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
  evidence:
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cataracts in 50% of patients"
    explanation: International registry documents cataracts in half of patients with ocular disease.
- name: Glaucoma
  category: Ophthalmologic
  description: >-
    Secondary glaucoma can complicate chronic bilateral uveitis and contributes
    to irreversible visual morbidity.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Glaucoma
    term:
      id: HP:0000501
      label: Glaucoma
  evidence:
  - reference: PMID:17009307
    reference_title: "Pediatric granulomatous arthritis: an international registry."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eye disease was bilateral in 21 of 22 patients and was complicated by glaucoma in 6 of 22 patients and by cataracts in 50% of patients"
    explanation: Glaucoma affected 6 of 22 patients with eye disease in the international registry.
- name: Vasculitis
  category: Cardiovascular
  description: >
    Systemic vasculitis affecting large and medium vessels, representing
    an expanded manifestation beyond the classic triad.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Vasculitis
    term:
      id: HP:0002633
      label: Vasculitis
  evidence:
  - reference: PMID:40350497
    reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively"
    explanation: Chinese cohort shows vasculitis in 27.7% of patients.
- name: Interstitial Lung Disease
  category: Respiratory
  description: >
    Granulomatous interstitial lung disease may occur as part of the
    expanded visceral manifestations of Blau syndrome.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Interstitial lung disease
    term:
      id: HP:0006530
      label: Abnormal pulmonary interstitial morphology
  evidence:
  - reference: PMID:40350497
    reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Incidence of vasculitis and interstitial lung disease were 27.7% and 17.0%, respectively"
    explanation: Chinese cohort shows interstitial lung disease in 17% of patients.
- name: Bone Dysplastic Changes
  category: Musculoskeletal
  description: >
    Dysplastic bony changes on radiographs, a previously unrecognized feature
    found in two-thirds of patients in the multicentre study. May suggest a
    role for NOD2 in bone morphogenesis and could have diagnostic value.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Skeletal dysplasia
    term:
      id: HP:0002652
      label: Skeletal dysplasia
  evidence:
  - reference: PMID:25416713
    reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Previously unknown dysplastic bony changes were found in two-thirds of patients"
    explanation: Multicentre study discovers bone dysplastic changes in 66% of patients, a novel finding with potential diagnostic value.
histopathology:
- name: Noncaseating Epithelioid Granulomas
  description: >-
    Skin or synovial tissue can show noncaseating granulomas composed of
    epithelioid histiocytes and multinucleated giant cells. This finding
    supports Blau syndrome in the appropriate early-onset multisystem context
    but is not disease-specific.
  evidence:
  - reference: PMID:17968944
    reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "noncaseating granulomata as their pathologic hallmark"
    explanation: The cohort identifies noncaseating granulomas as the defining histopathologic feature.
  - reference: PMID:36192768
    reference_title: "Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her skin biopsy revealed noncaseating granulomas inflammation with multinucleated giant cells."
    explanation: A genetically confirmed case documents noncaseating granulomas with multinucleated giant cells.
diagnosis:
- name: Early-onset granulomatous triad and multisystem assessment
  description: >-
    Suspect Blau syndrome in a child with papular granulomatous dermatitis,
    boggy arthritis or tenosynovitis, and uveitis, even when the full triad has
    not yet appeared. Assess for vascular, pulmonary, renal, hepatic,
    neurologic, and other systemic manifestations.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: NCIT:C18020
      label: Diagnostic Procedure
  evidence:
  - reference: PMID:40456554
    reference_title: "Blau Syndrome (Juvenile Systemic Granulomatosis): State-Of-The-Art Review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain-of-function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated."
    explanation: The review defines the clinical pattern that should prompt diagnostic evaluation.
  - reference: PMID:19479837
    reference_title: "NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NOD2-associated PGA can be a multisystem disorder with significant visceral involvement."
    explanation: The combined cohorts support evaluation beyond the classic triad.
- name: NOD2 molecular genetic testing
  description: >-
    Sequence NOD2, with an autoinflammatory gene panel or broader testing when
    appropriate, to identify a heterozygous pathogenic or likely pathogenic
    variant. Variant interpretation must integrate phenotype, segregation,
    penetrance, and functional data rather than treating every NOD2 variant as
    diagnostic.
  diagnosis_term:
    preferred_term: molecular genetic testing
    term:
      id: NCIT:C19770
      label: Molecular Analysis
  evidence:
  - reference: PMID:37941393
    reference_title: "Molecular diagnostic yield for Blau syndrome in previously diagnosed juvenile idiopathic arthritis with uveitis or cutaneous lesions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted NOD2 sequencing established the molecular diagnosis of Blau syndrome in nearly one-fifth of these cases and provided clinically relevant information for patient-care decisions."
    explanation: Targeted sequencing reclassified a substantial selected subgroup previously diagnosed with JIA.
  - reference: PMID:38927735
    reference_title: "Blau Syndrome: Challenging Molecular Genetic Diagnostics of Autoinflammatory Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The probands from families 1 and 2 carried pathogenic variants in NOD2 (NM_022162.3): c.1001G>A p.(Arg334Gln) and c.1000C>T p.(Arg334Trp), respectively."
    explanation: The case series illustrates molecular confirmation and the need to distinguish pathogenic variants from variants of uncertain significance.
- name: Skin biopsy for granulomatous inflammation
  description: >-
    Biopsy of an active skin lesion can demonstrate noncaseating granulomas and
    multinucleated giant cells. Histology is supportive rather than sufficient
    because other inflammatory, infectious, and immunodeficiency disorders can
    also be granulomatous.
  diagnosis_term:
    preferred_term: skin biopsy
    term:
      id: NCIT:C51692
      label: Skin Biopsy
  evidence:
  - reference: PMID:36192768
    reference_title: "Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her skin biopsy revealed noncaseating granulomas inflammation with multinucleated giant cells."
    explanation: The genetically confirmed case demonstrates the supportive biopsy pattern.
- name: Comprehensive ophthalmic examination
  description: >-
    Slit-lamp and posterior-segment assessment are needed at diagnosis because
    ocular disease can be bilateral and may progress despite apparently
    controlled systemic inflammation.
  diagnosis_term:
    preferred_term: eye examination
    term:
      id: NCIT:C38060
      label: Eye Examination
  evidence:
  - reference: PMID:25416713
    reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Ocular disease was documented in 25 of 31 patients, with vitreous inflammation in 64% and moderate-severe visual loss in 33%"
    explanation: The high ocular burden supports comprehensive eye evaluation at diagnosis.
differential_diagnoses:
- name: Juvenile Idiopathic Arthritis
  disease_term:
    preferred_term: juvenile idiopathic arthritis
    term:
      id: MONDO:0011429
      label: juvenile idiopathic arthritis
  description: >-
    Juvenile idiopathic arthritis can combine childhood arthritis and uveitis,
    but papular granulomatous dermatitis, boggy tenosynovitis, noncaseating
    granulomas, or a familial pattern should prompt reassessment for Blau
    syndrome.
  distinguishing_features:
  - Heterozygous pathogenic NOD2 variant supports Blau syndrome
  - Noncaseating granulomatous dermatitis or synovitis supports Blau syndrome
  - The complete dermatitis-arthritis-uveitis triad is more characteristic of Blau syndrome
  evidence:
  - reference: PMID:37941393
    reference_title: "Molecular diagnostic yield for Blau syndrome in previously diagnosed juvenile idiopathic arthritis with uveitis or cutaneous lesions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Targeted sequencing was conducted on NOD2 gene to detect diagnostic variants classified as pathogenic or likely pathogenic for Blau syndrome."
    explanation: The diagnostic-yield study directly addresses selected patients initially classified as JIA.
genetic:
- name: NOD2
  association: Heterozygous pathogenic variants
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: NOD2
    term:
      id: hgnc:5331
      label: NOD2
  inheritance:
  - name: Autosomal dominant
    evidence:
    - reference: PMID:17968944
      reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "NOD2 analysis revealed 1 heterozygous mutation in each patient, and familial studies confirmed its full penetrance"
      explanation: Familial segregation supports autosomal dominant inheritance.
    - reference: PMID:36192768
      reference_title: "Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A novel C483W NOD2 mutation was identify in the proband and her asymptomatic father."
      explanation: The asymptomatic variant-bearing father demonstrates that penetrance can be incomplete.
  features: >-
    Blau syndrome is caused by heterozygous pathogenic NOD2 (CARD15) variants,
    usually missense variants in or near the central nucleotide-binding/NACHT
    domain. p.Arg334Trp and p.Arg334Gln are recurrent hotspots. Variants may be
    inherited or de novo, and penetrance and phenotype can vary; a NOD2 variant
    of uncertain significance is not sufficient for diagnosis.
  variants:
  - name: p.Arg334Trp (R334W)
    description: >-
      Recurrent pathogenic missense variant c.1000C>T in the NOD/NACHT domain.
      It was the most frequent single variant in the international prospective
      cohort.
    evidence:
    - reference: PMID:25416713
      reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Of the 31 patients, 11 carried the p.R334W NOD2 mutation, 9 the p.R334Q and 11 various other NOD2 missense mutations"
      explanation: Multicentre cohort confirms p.R334W is the single most common Blau syndrome mutation.
  - name: p.Arg334Gln (R334Q)
    description: >-
      Recurrent pathogenic missense variant c.1001G>A affecting the same
      NACHT-domain residue as p.Arg334Trp.
    evidence:
    - reference: PMID:25416713
      reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Of the 31 patients, 11 carried the p.R334W NOD2 mutation, 9 the p.R334Q and 11 various other NOD2 missense mutations"
      explanation: Multicentre cohort documents p.R334Q in 9 of 31 Blau patients alongside R334W.
  evidence:
  - reference: PMID:11528384
    reference_title: "CARD15 mutations in Blau syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We have identified three missense mutations in the nucleotide-binding domain (NBD) of CARD15/NOD2 in four French and German families with Blau syndrome"
    explanation: Landmark paper identifying CARD15/NOD2 as the causative gene with mutations in the NBD.
  - reference: PMID:25416713
    reference_title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of the 31 patients, 11 carried the p.R334W NOD2 mutation, 9 the p.R334Q and 11 various other NOD2 missense mutations; 20 patients were sporadic and 11 from five BS pedigrees"
    explanation: Multicentre study shows R334W and R334Q are the most common mutations.
  - reference: PMID:17968944
    reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NOD2 analysis revealed 1 heterozygous mutation in each patient, and familial studies confirmed its full penetrance"
    explanation: Confirms heterozygous mutations with full penetrance.
  - reference: PMID:37604356
    reference_title: "Distinct NOD2 mutations reported in three families with Blau syndrome (BS) from a single center in India - Case series and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The first family had three affected members where the mother and her two children had skin changes, polyarthritis and a pathogenic mutation in NOD2 gene (exon 4, c.1000C > T, p.Arg334Trp) suggesting BS"
    explanation: Indian case series confirms R334W (Arg334Trp) in a familial Blau syndrome pedigree with classic triad.
  - reference: CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z
    reference_title: "NOD2 / Blau syndrome (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NOD2 | HGNC:5331 | Blau syndrome | MONDO:0008523 | AD | Definitive"
    explanation: ClinGen classifies the NOD2-Blau syndrome gene-disease relationship as definitive with autosomal dominant inheritance.
  - reference: PMID:36192768
    reference_title: "Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We reported a novel C483W NOD2 mutation underlining BS with incomplete penetrance."
    explanation: This family broadens the allelic spectrum and limits claims of universal penetrance.
treatments:
- name: Regular Ophthalmic Monitoring
  description: >-
    Repeated slit-lamp and posterior-segment examinations are essential because
    ocular inflammation can become chronic panuveitis and systemic inflammatory
    markers may not reflect intraocular activity.
  action_category: MONITORING
  treatment_term:
    preferred_term: eye examination
    term:
      id: NCIT:C38060
      label: Eye Examination
  evidence:
  - reference: PMID:38180755
    reference_title: "Long-Term Visual Outcome of Patients with Blau Syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Uveitis associated with Blau syndrome commonly leads to severe, chronic panuveitis, requiring long-term systemic immunosuppression."
    explanation: Longitudinal ocular outcomes justify sustained specialist monitoring.
- name: Systemic Corticosteroids as Bridging Therapy
  description: >-
    Systemic glucocorticoids can suppress acute inflammatory activity while a
    steroid-sparing regimen is established. Long-term monotherapy is generally
    inadequate and exposes children to cumulative toxicity.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: corticosteroid agent therapy
    term:
      id: NCIT:C122080
      label: Systemic Corticosteroid Therapy
    therapeutic_agent:
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
  evidence:
  - reference: PMID:37735224
    reference_title: "Management of Blau syndrome: review and proposal of a treatment algorithm."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "High doses of corticosteroids are considered as a bridging therapy in Blau syndrome."
    explanation: The proposed management algorithm limits high-dose corticosteroids to a bridging role.
  - reference: PMID:40350497
    reference_title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Approximately 95.7% patients (45 patients) were treated with combination of prednisolone and methotrexate"
    explanation: The cohort documents frequent combined use but does not isolate corticosteroid efficacy.
- name: Methotrexate Steroid-Sparing Therapy
  description: >-
    Methotrexate is commonly used for articular or ocular disease as a
    steroid-sparing conventional DMARD. Evidence is observational, and pooled
    uveitis data do not establish it as a preferred agent.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: immunosuppressive therapy
    term:
      id: NCIT:C15261
      label: Immunosuppressive Therapy
    therapeutic_agent:
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
  target_phenotypes:
  - preferred_term: Polyarticular arthritis
    term:
      id: HP:0005764
      label: Polyarticular arthritis
  - preferred_term: Panuveitis
    term:
      id: HP:0012121
      label: Panuveitis
  evidence:
  - reference: PMID:37735224
    reference_title: "Management of Blau syndrome: review and proposal of a treatment algorithm."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Methotrexate should be initiated if the patient has articular or ocular involvement."
    explanation: The review's proposed algorithm places methotrexate after bridging corticosteroids.
  - reference: PMID:40147219
    reference_title: "Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The data show that there is not enough evidence to establish a preferred treatment for managing uveitis in BS."
    explanation: The meta-analysis limits confidence in methotrexate or any other preferred systemic uveitis regimen.
- name: Anti-TNF Biologic Therapy
  description: >-
    Monoclonal TNF inhibitors such as adalimumab or infliximab are used for
    persistent uveitis or arthritis. Cohorts show frequent initial responses,
    but relapse and secondary loss of efficacy are common, and comparative
    evidence remains insufficient.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: anti-TNF biologic therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: adalimumab
      term:
        id: NCIT:C65216
        label: Adalimumab
    - preferred_term: infliximab
      term:
        id: NCIT:C1789
        label: Infliximab
  target_phenotypes:
  - preferred_term: Polyarticular arthritis
    term:
      id: HP:0005764
      label: Polyarticular arthritis
  - preferred_term: Panuveitis
    term:
      id: HP:0012121
      label: Panuveitis
  target_mechanisms:
  - target: Dysregulated Innate Cytokine Response
    treatment_effect: INHIBITS
    evidence:
    - reference: PMID:35711422
      reference_title: "Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "anti-TNF treatment corrects the abnormalities associated with Blau syndrome, even in the presence of IFNγ"
      explanation: Patient-derived macrophages provide mechanistic support for TNF blockade.
  evidence:
  - reference: PMID:41673771
    reference_title: "Clinical features, treatment strategies, and long-term outcomes of Blau syndrome: a 10-year experience from a Chinese cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While 6 (46.2%) patients achieved sustained stability, relapse or secondary loss of efficacy occurred in 6 (46.2%) patients, necessitating treatment adjustments."
    explanation: Long-term follow-up documents both durable control and frequent secondary failure.
  - reference: PMID:40147219
    reference_title: "Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proportion of children showing improvement of uveitis was 20 % (95 % CI 2-46) and 22 % (95 % CI3-47) for cDMARDs and bDMARDs respectively (χ20.23, p = 0.631)."
    explanation: The pooled literature does not demonstrate superior uveitis improvement with biologic DMARDs.
- name: Salvage IL-1 Receptor Antagonist Therapy
  description: >-
    Anakinra has produced improvement in an individual refractory case, but
    evidence is too limited to establish general efficacy or a preferred place
    in therapy.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: IL-1 receptor antagonist therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: anakinra
      term:
        id: CHEBI:231683
        label: Anakinra
  target_mechanisms:
  - target: Dysregulated Innate Cytokine Response
    treatment_effect: INHIBITS
    evidence:
    - reference: PMID:17968944
      reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "the pathogenesis of pediatric granulomatous arthritis may involve interleukin-1-mediated events"
      explanation: The cohort provides limited clinical and cytokine evidence for an IL-1-responsive branch.
  evidence:
  - reference: PMID:17968944
    reference_title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the patient who received anakinra treatment, all clinical inflammatory symptoms improved and plasma cytokine levels normalized"
    explanation: This is single-patient evidence and is retained only as a salvage-treatment signal.
- name: Emerging Tofacitinib Therapy
  description: >-
    Tofacitinib suppresses IFN-gamma-induced NOD2 expression in cell models and
    has retrospective clinical evidence in refractory Blau syndrome. It remains
    an emerging option under prospective evaluation rather than an established
    standard.
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: JAK inhibitor therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tofacitinib
      term:
        id: CHEBI:71200
        label: tofacitinib
  target_phenotypes:
  - preferred_term: Polyarticular arthritis
    term:
      id: HP:0005764
      label: Polyarticular arthritis
  - preferred_term: Panuveitis
    term:
      id: HP:0012121
      label: Panuveitis
  target_mechanisms:
  - target: IFN-γ-Primed Mutant NOD2 Inflammatory Signaling
    treatment_effect: INHIBITS
    evidence:
    - reference: PMID:37415984
      reference_title: "Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Tofacitinib suppressed the induction of NOD2 by IFNγ, thereby inhibiting the production of pro-inflammatory cytokines"
      explanation: The cell model directly supports inhibition of the IFN-gamma/NOD2 branch.
  evidence:
  - reference: PMID:37415984
    reference_title: "Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Tofacitinib suppressed the induction of NOD2 by IFNγ, thereby inhibiting the production of pro-inflammatory cytokines"
    explanation: iPSC-derived myeloid cell studies demonstrate tofacitinib suppresses NOD2 expression and cytokine production.
  - reference: PMID:40233998
    reference_title: "Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TOF could be an effective therapeutic option for patients with BS who demonstrate resistance to TNFi or corticosteroids."
    explanation: The multicenter retrospective cohort supplies clinical support while retaining nonrandomized uncertainty.
clinical_trials:
- name: NCT06660329
  phase: PHASE_IV
  status: ENROLLING_BY_INVITATION
  description: >-
    Prospective cohort study evaluating the efficacy and safety of tofacitinib
    in 30 children with refractory Blau syndrome. The registry lists estimated
    completion in October 2028.
  target_phenotypes:
  - preferred_term: Polyarticular arthritis
    term:
      id: HP:0005764
      label: Polyarticular arthritis
  - preferred_term: Panuveitis
    term:
      id: HP:0012121
      label: Panuveitis
  evidence:
  - reference: clinicaltrials:NCT06660329
    reference_title: "Efficacy and Safety of Tofacitinib in Patients with Refractory Blau Syndrome: a Prospective Cohort Study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is a prospective cohort study to observe the efficacy and safety of Tofacitinib in children with Blau syndrome (BS)"
    explanation: The registry defines the prospective refractory-Blau cohort and intervention.
- name: NCT06688838
  phase: NOT_APPLICABLE
  status: ENROLLING_BY_INVITATION
  description: >-
    Retrospective multicenter observational study comparing glucocorticoid plus
    conventional DMARD, TNF-inhibitor, and tofacitinib-treated Blau syndrome
    cohorts; the associated results have been published.
  target_phenotypes:
  - preferred_term: Polyarticular arthritis
    term:
      id: HP:0005764
      label: Polyarticular arthritis
  - preferred_term: Panuveitis
    term:
      id: HP:0012121
      label: Panuveitis
  evidence:
  - reference: clinicaltrials:NCT06688838
    reference_title: "Exploring the Clinical Features and Factors Related to Efficacy in Blau Syndrome: A Retrospective Observational Study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort."
    explanation: The registry summary specifies the observational treatment-comparison objective.
  - reference: PMID:40233998
    reference_title: "Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 5-year, multicenter, retrospective, observational study (ClinicalTrials.gov: NCT06688838) was conducted across 7 centers, focusing on genetic profiles and the clinical manifestations of the cohort."
    explanation: The publication links the reported retrospective study directly to the registry.
animal_models:
- species: Mus musculus
  description: >-
    Mice carrying a Blau-associated NOD2 mutation show defective
    NOD2-mediated cross-regulation and enhanced antibody-induced arthritis,
    modeling one proposed route from altered innate regulation to joint
    inflammation.
  evidence:
  - reference: PMID:36189261
    reference_title: "Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Similarly, mice bearing a Blau mutation exhibit enhanced anti-collagen antibody-induced arthritis."
    explanation: The mutation-bearing mouse demonstrates increased susceptibility to experimentally induced joint inflammation.
datasets:
- accession: geo:GSE98454
  title: "Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages"
  description: >-
    Bulk RNA sequencing of Blau syndrome p.R334W iPSC-derived macrophages,
    CRISPR-corrected isogenic cells, and wild-type control cells under untreated,
    IFN-gamma, MDP, and combined stimulation conditions.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
    cell_type_term:
      preferred_term: macrophage
      term:
        id: CL:0000235
        label: macrophage
  conditions:
  - Blau syndrome p.Arg334Trp
  - CRISPR-corrected isogenic control
  - wild-type control
  publication: PMID:28587749
  evidence:
  - reference: PMID:28587749
    reference_title: "Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "RNA sequencing analysis revealed distinct transcriptional profiles of mutant macrophages both before and after IFN-γ treatment."
    explanation: The publication describes the RNA-seq comparison represented by GSE98454.
  notes: >-
    GEO GSE98454 contains 12 samples spanning mutant, gene-corrected, and
    wild-type iPSC-derived macrophages with IFN-gamma and/or MDP perturbation.
discussions:
- discussion_id: controversy_blau_nod2_signaling_model
  prompt: >-
    How can IFN-gamma-primed ligand-independent NF-kappaB activation be
    reconciled with loss of canonical NOD2-RIPK2-IRF4 cross-regulation in Blau
    syndrome?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#IFN-γ-Primed Mutant NOD2 Inflammatory Signaling
  - pathophysiology#Defective NOD2-RIPK2-IRF4 Cross-Regulation
  rationale: >-
    Both models use disease-relevant variants but differ in cell system,
    stimulation context, and measured pathway output. The entry therefore
    models them as potentially complementary branches rather than collapsing
    genetic gain of function into universal constitutive NF-kappaB activation.
  evidence:
  - reference: PMID:28587749
    reference_title: "Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "IFN-γ treatment induced ligand-independent nuclear factor κB activation and proinflammatory cytokine production."
    explanation: Isogenic and patient-derived macrophages support a priming-dependent activation model.
  - reference: PMID:36189261
    reference_title: "Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "NOD2 plasmids expressing various Blau mutations in HEK293 cells result in reduced NOD2 activation of RIPK2 and correspondingly reduced NOD2 activation of NF-κB."
    explanation: HEK293 cell experiments support reduced canonical NOD2-RIPK2 and NF-kappaB signaling.
- discussion_id: gap_blau_comparative_treatment_efficacy
  prompt: >-
    Which steroid-sparing or biologic regimen best prevents irreversible ocular
    and articular damage in Blau syndrome?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#Methotrexate Steroid-Sparing Therapy
  - treatments#Anti-TNF Biologic Therapy
  - treatments#Salvage IL-1 Receptor Antagonist Therapy
  - treatments#Emerging Tofacitinib Therapy
  rationale: >-
    Published treatment evidence is dominated by case reports and small
    observational cohorts. Even the uveitis meta-analysis could not identify a
    preferred systemic treatment, and long-term TNF-inhibitor responses can be
    lost.
  evidence:
  - reference: PMID:40147219
    reference_title: "Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The data show that there is not enough evidence to establish a preferred treatment for managing uveitis in BS."
    explanation: The systematic review explicitly identifies comparative uncertainty.
  - reference: PMID:41673771
    reference_title: "Clinical features, treatment strategies, and long-term outcomes of Blau syndrome: a 10-year experience from a Chinese cohort."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "relapse or secondary loss of efficacy occurred in 6 (46.2%) patients, necessitating treatment adjustments."
    explanation: Long-term observational data demonstrate that initial biologic response may not persist.
- discussion_id: interpretation_blau_nod2_variant_penetrance
  prompt: >-
    How should a rare NOD2 variant be interpreted when the phenotype or family
    segregation is incomplete?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - genetic#NOD2
  rationale: >-
    Although the gene-disease relationship is definitive and many hotspot
    variants are highly penetrant, incomplete penetrance and variants of
    uncertain significance occur. Classification must integrate phenotype,
    segregation, population data, and functional evidence.
  evidence:
  - reference: PMID:36192768
    reference_title: "Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A novel C483W NOD2 mutation was identify in the proband and her asymptomatic father."
    explanation: The family directly demonstrates incomplete penetrance.
  - reference: PMID:38927735
    reference_title: "Blau Syndrome: Challenging Molecular Genetic Diagnostics of Autoinflammatory Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variants of unknown significance pose a significant challenge regarding their contribution to etiopathogenesis of autoinflammatory diseases."
    explanation: The case series cautions against equating an uncertain variant with a molecular diagnosis.
references:
- reference: PMID:40456554
  title: "Blau Syndrome (Juvenile Systemic Granulomatosis): State-Of-The-Art Review."
  findings: []
- reference: CGGV:assertion_1fd650d7-6a84-4b33-b86e-d34cab5b7d57-2020-10-07T171807.983Z
  title: "NOD2 / Blau syndrome (Definitive)"
  findings: []
- reference: PMID:41678017
  title: "NOD2-Related Multisystem Inflammatory Disorders and Recent Advances."
  findings: []
- reference: PMID:36192768
  title: "Incomplete penetrance of NOD2 C483W mutation underlining Blau syndrome."
  findings: []
- reference: PMID:17968944
  title: "NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort."
  findings: []
- reference: PMID:17009307
  title: "Pediatric granulomatous arthritis: an international registry."
  findings: []
- reference: PMID:38180755
  title: "Long-Term Visual Outcome of Patients with Blau Syndrome."
  findings: []
- reference: PMID:41673771
  title: "Clinical features, treatment strategies, and long-term outcomes of Blau syndrome: a 10-year experience from a Chinese cohort."
  findings: []
- reference: PMID:11528384
  title: "CARD15 mutations in Blau syndrome."
  findings: []
- reference: PMID:28587749
  title: "Pluripotent stem cell models of Blau syndrome reveal an IFN-γ-dependent inflammatory response in macrophages."
  findings: []
- reference: PMID:36189261
  title: "Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function."
  findings: []
- reference: PMID:35711422
  title: "Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis."
  findings: []
- reference: PMID:19479837
  title: "NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain."
  findings: []
- reference: PMID:40350497
  title: "Long-term prognosis of 47 pediatric patients with Blau syndrome in China."
  findings: []
- reference: PMID:25416713
  title: "Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes."
  findings: []
- reference: PMID:38927735
  title: "Blau Syndrome: Challenging Molecular Genetic Diagnostics of Autoinflammatory Disease."
  findings: []
- reference: PMID:37941393
  title: "Molecular diagnostic yield for Blau syndrome in previously diagnosed juvenile idiopathic arthritis with uveitis or cutaneous lesions."
  findings: []
- reference: PMID:37604356
  title: "Distinct NOD2 mutations reported in three families with Blau syndrome (BS) from a single center in India - Case series and review of literature."
  findings: []
- reference: PMID:37735224
  title: "Management of Blau syndrome: review and proposal of a treatment algorithm."
  findings: []
- reference: PMID:40147219
  title: "Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis."
  findings: []
- reference: PMID:37415984
  title: "Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome."
  findings: []
- reference: PMID:40233998
  title: "Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China."
  findings: []
- reference: clinicaltrials:NCT06660329
  title: "Efficacy and Safety of Tofacitinib in Patients with Refractory Blau Syndrome: a Prospective Cohort Study"
  findings: []
- reference: clinicaltrials:NCT06688838
  title: "Exploring the Clinical Features and Factors Related to Efficacy in Blau Syndrome: A Retrospective Observational Study"
  findings: []
review_notes: >-
  This review treats familial Blau syndrome and sporadic early-onset sarcoidosis
  as one NOD2-associated disease spectrum; the two subtype records describe
  inheritance occurrence rather than distinct clinical entities. The causal
  pathograph no longer assumes that every pathogenic NOD2 variant produces
  universal constitutive NF-kappaB activation. It preserves both the
  IFN-gamma-primed ligand-independent model and the defective
  NOD2-RIPK2-IRF4-cross-regulation model as evidence-backed, unresolved
  branches. Evidence from a different NOD2-associated early-onset inflammatory
  bowel phenotype was removed from the Blau mechanism, and the prior L469F
  variant entry was removed because its cited snippet did not identify that
  allele. Glaucoma was added from direct registry evidence, while the many
  source-comparison phenotype candidates were not bulk imported without
  disease-specific exact evidence. Treatment statements are bounded to small
  cohorts, case-level observations, a systematic review, and ongoing studies;
  no standardized management guideline exists. ClinicalTrials.gov statuses
  were checked on 2026-07-23: NCT06660329 and NCT06688838 were enrolling by
  invitation. The broad CoRDS rare-disease registry was not modeled as a
  Blau-specific trial. GeneReviews coverage was rechecked on 2026-07-24: the
  repository-local GeneReviews detector and a title scan across all locally
  cached GeneReviews records found no chapter for Blau syndrome, early-onset
  sarcoidosis, or NOD2, and the official NCBI GTR Blau condition row exposes no
  GeneReviews link. No GeneReviews reference was therefore tagged or mined.
  For HP:0006530, `term.label` intentionally retains the canonical HPO label
  "Abnormal pulmonary interstitial morphology"; `preferred_term` uses HPO's
  exact synonym "Interstitial lung disease" to match the clinical wording in
  the cited cohort.

📚

References & Deep Research